OMI

Executives Sell While Major Shareholder Buys: The Stark Contrast in Insider Trading as Owens & Minor ($OMI) Shares Plunge 60%

04/11/2025 01:55

Medical supply company Owens & Minor ($OMI) has seen its stock price plummet by approximately 60% over the past 10 months, while displaying a stark contrast in insider trading patterns that has caught investors' attention. In June 2024, multiple high-ranking executives at $OMI simultaneously sold their shares. Alexander J. Bruni, EVP, sold 10,568 shares (approximately $187,000), Snehashish Sarkar, EVP, sold 9,980 shares (approximately $173,000), Director Mark A. Beck sold 9,344 shares (approximately $161,000), and Perry A. Bernocchi, EVP, sold 20,015 shares (approximately $350,000). At that time, the stock was trading around $17 per share. This concentrated selling is particularly noteworthy as it occurred just before the company's stock price began its downward trajectory. Subsequently, $OMI's share price steadily declined, falling to around $13 by the end of 2024. During this period, smaller sales by executives including Jonathan A. Leon, SVP, and Snehashish Sarkar, now CIO, continued. Notably, Leon, as EVP, sold an additional 5,282 shares (approximately $62,000) on November 21. However, February 2025 marked a critical inflection point with a precipitous drop in the company's stock price. On February 3, $OMI announced preliminary fourth-quarter results that fell short of market expectations. Projected revenue of $2.67-$2.70 billion missed analysts' estimates of $2.73 billion. This news sent the stock plummeting approximately 35% in a single day, from $14.24 to $9.23. Following this dramatic price drop, an interesting insider trading pattern emerged. Major shareholder Coliseum Capital Management embarked on an aggressive share purchase campaign beginning in late February. From February 28 to March 4, they acquired approximately 2.9 million shares (worth about $27.4 million), followed by an additional 940,000 shares (approximately $7.36 million) from early to mid-April. These substantial purchases were made when the stock had fallen below $9 per share. Coliseum Capital's aggressive buying action can be interpreted as a signal of confidence in $OMI's long-term value. Particularly notable is that they continued purchasing even after President Trump's April 3 announcement of reciprocal tariffs caused a general decline in medical supply company stocks. According to the announcement, tariffs would be imposed on China, the EU, Japan, South Korea, and Taiwan, which was expected to negatively impact medical supply companies that source personal protective equipment from Southeast Asia. $OMI currently faces significant financial challenges. The company's debt-to-equity ratio stands at an elevated 394.71%, and it recorded a net loss of $363 million on an annualized basis. Additionally, to finance the $1.36 billion Rotech Healthcare acquisition announced in July 2024, the company announced a $600 million senior secured notes offering in March 2025. Despite these challenges, $OMI's management has presented a relatively optimistic outlook for 2025. The company projects revenue between $10.85 billion and $11.15 billion, with adjusted EPS forecasted at $1.60-$1.85. This suggests the stock might be undervalued at its current price of around $7, with a forward P/E of approximately 4. Medical supply industry analysts suggest that while $OMI may face short-term difficulties due to tariff burdens and debt pressure, technological investments in the Products & Healthcare Services segment and growth potential in the Patient Direct segment could drive long-term recovery. In particular, the successful completion of the Rotech Healthcare acquisition could strengthen the company's position in the home care market. Currently, the average analyst rating for $OMI is 'Hold,' with a median 12-month price target of $12.50, suggesting an upside potential of approximately 78% from the current price. However, many of these targets were established before the major stock decline in February and may be subject to downward revisions. In conclusion, $OMI's insider trading patterns reflect a company navigating between short-term challenges and long-term value. The executives' initial selling might have anticipated upcoming challenges, while the major shareholder's recent large-scale purchases suggest that the current depressed stock price may offer a long-term investment opportunity. Investors should closely monitor $OMI's debt situation, the progress of the Rotech Healthcare acquisition, and the actual impact of tariff policies.

You can receive notifications when news is published.